Literature DB >> 28191863

Ulinastatin downregulates TLR4 and NF-kB expression and protects mouse brains against ischemia/reperfusion injury.

Xiaofang Li1, Likai Su1, Xiangjian Zhang2,3, Cong Zhang2,3, Lina Wang2,3, Yaoru Li2,3, Ye Zhang2,3, Tingting He2,3, Xingyuan Zhu2,3, Lili Cui2,3.   

Abstract

BACKGROUND: Inflammatory damage plays an important role in ischemic stroke and provides potential targets for therapy. Ulinastatin (UTI), a drug used to treat shock and acute pancreatitis in clinic, has attracted attention for its protective effects through immunomodulatory and anti-inflammatory properties. However, the effect of UTI in the acute phase of cerebral ischemia/reperfusion (I/R) is not clear. This study is to investigate the potential neuroprotective effect of UTI and explore its underlying mechanisms.
METHODS: Male CD-1 mice were subjected to transient middle cerebral artery occlusion (tMCAO) and randomly assigned into four groups: Sham (sham-operated) group, tMCAO (tMCAO + 0.9% saline) group, UTI-L (tMCAO + UTI 1500 U/100 g), and UTI-H (tMCAO + UTI 3000 U/100 g) group. UTI was administered immediately after reperfusion in the UTI-L and UTI-H groups. About 24 h after the reperfusion, the neurological deficit, brain water content, and infarct volume were detected. Immunohistochemistry, western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to detect the expression of TLR4 and NF-κB in the ischemic cerebral cortex.
RESULTS: Compared with tMCAO group, both UTI-L and UTI-H groups dramatically ameliorated neurological deficit (p < 0.05), lessened the brain water content (p < 0.05) and infarct volume (p < 0.05), and decreased the expression of TLR4 and NF-κB.
CONCLUSION: These results showed that UTI protected the brain against ischemic injury which may be due to the alleviation of inflammation reaction in early stage through downregulating TLR4 and NF-κB expression.

Entities:  

Keywords:  Cerebral ischemia/reperfusion; inflammatory; nuclear factor-kappa B; toll-like receptor 4; ulinastatin

Mesh:

Substances:

Year:  2017        PMID: 28191863     DOI: 10.1080/01616412.2017.1286541

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  25 in total

1.  Rosmarinic Acid Mitigates Lipopolysaccharide-Induced Neuroinflammatory Responses through the Inhibition of TLR4 and CD14 Expression and NF-κB and NLRP3 Inflammasome Activation.

Authors:  Yicong Wei; Jianxiong Chen; Yonghong Hu; Wei Lu; Xiaoqin Zhang; Ruiguo Wang; Kedan Chu
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 2.  Central Noradrenergic Agonists in the Treatment of Ischemic Stroke-an Overview.

Authors:  Zohi Sternberg; B Schaller
Journal:  Transl Stroke Res       Date:  2019-07-20       Impact factor: 6.829

3.  [Mechanism of ulinastatin in reducing lung inflammatory injury in rats with hemorrhagic shock].

Authors:  Ying Chen; Zhipeng Xu; Qi Song; Zhenjie Wang; Zhong Ji; Zhaolei Qiu; Feng Cheng; Hai Jiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-10-30

4.  Neuroprotective effects of inter-alpha inhibitor proteins after hypoxic-ischemic brain injury in neonatal rats.

Authors:  Xiaodi Chen; Sakura Nakada; John E Donahue; Ray H Chen; Richard Tucker; Joseph Qiu; Yow-Pin Lim; Edward G Stopa; Barbara S Stonestreet
Journal:  Exp Neurol       Date:  2019-03-23       Impact factor: 5.330

5.  Neurovascular Unit Alterations in the Growth-Restricted Newborn Are Improved Following Ibuprofen Treatment.

Authors:  Kirat K Chand; Stephanie M Miller; Gary J Cowin; Lipsa Mohanty; Jany Pienaar; Paul B Colditz; Stella Tracey Bjorkman; Julie A Wixey
Journal:  Mol Neurobiol       Date:  2021-11-26       Impact factor: 5.590

6.  7-Chloro-4-(Phenylselanyl) Quinoline Is a Novel Multitarget Therapy to Combat Peripheral Neuropathy and Comorbidities Induced by Paclitaxel in Mice.

Authors:  Jaini J Paltian; Angélica S Dos Reis; Amanda W S Martins; Eduardo B Blödorn; Eduardo N Dellagostin; Liane K Soares; Ricardo F Schumacher; Vinícius F Campos; Diego Alves; Cristiane Luchese; Ethel Antunes Wilhelm
Journal:  Mol Neurobiol       Date:  2022-08-15       Impact factor: 5.682

Review 7.  Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight.

Authors:  Priyanka Saklani; Heena Khan; Thakur Gurjeet Singh; Saurabh Gupta; Amarjot Kaur Grewal
Journal:  Mol Biol Rep       Date:  2022-06-03       Impact factor: 2.742

Review 8.  miRNA Involvement in Cerebral Ischemia-Reperfusion Injury.

Authors:  Maria-Adriana Neag; Andrei-Otto Mitre; Codrin-Constantin Burlacu; Andreea-Ioana Inceu; Carina Mihu; Carmen-Stanca Melincovici; Marius Bichescu; Anca-Dana Buzoianu
Journal:  Front Neurosci       Date:  2022-06-10       Impact factor: 5.152

9.  Attenuation of the Induction of TLRs 2 and 4 Mitigates Inflammation and Promotes Neurological Recovery After Focal Cerebral Ischemia.

Authors:  Koteswara Rao Nalamolu; Siva Reddy Challa; Casimir A Fornal; Natalia A Grudzien; Laura C Jorgenson; Mouneeb M Choudry; Nathan J Smith; Cassandra J Palmer; David M Pinson; Jeffrey D Klopfenstein; Krishna Kumar Veeravalli
Journal:  Transl Stroke Res       Date:  2021-01-11       Impact factor: 6.800

10.  MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease.

Authors:  Longping Yao; Yongyi Ye; Hengxu Mao; Fengfei Lu; Xiaozheng He; Guohui Lu; Shizhong Zhang
Journal:  J Neuroinflammation       Date:  2018-01-12       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.